Comparison of Efficacy and Side Effects of Oral Baclofen Versus Tizanidine Therapy with Adjuvant Botulinum Toxin Type A in Children With Cerebral Palsy and Spastic Equinus Foot Deformity
作者： Alper I. Dai , Sefika N. Aksoy , Abdullah T. Demiryürek
关键词: Medicine 、 Adverse effect 、 Botulinum toxin 、 Cerebral palsy 、 Gross motor skill 、 Anesthesia 、 Baclofen 、 Foot deformity 、 Tizanidine 、 Spastic
摘要: This retrospective study aimed to compare the therapeutic response, including side effects, for oral baclofen versus tizanidine therapy with adjuvant botulinum toxin type A in a group of 64 pediatric patients diagnosed static encephalopathy and spastic equinus foot deformity. Following treatment, clinical improvement led gradual reduction or dosing one-third former dose. Gross Motor Functional Measure Caregiver Health Questionnaire scores were markedly elevated post-botulinum (Gross Measure: 74.45 ± 3.72; Questionnaire: 72.43 4.29) significantly higher than 68.23 2.66; 67.53 2.67, P < .001). These findings suggest that combined use low dose treating children cerebral palsy appears be more effective has fewer effects A.
sagepub.com
sci-hub.se 参考文章(34)
Kurenkov Al, Gotlib VIa, Brin Il, The use of sirdalud in cerebral palsy in children Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova. ,vol. 99, pp. 30- ,(1999)
B. Brandl-Hesse, M. Gregoric, B. Doll, U. Seidel, S. Hesse, Lower limb muscle activity in ambulatory children with cerebral palsy before and after the treatment with Botulinum toxin A. Restorative Neurology and Neuroscience. ,vol. 17, pp. 1- 8 ,(2000)
Edward M. Goldstein, Safety of High-Dose Botulinum Toxin Type A Therapy for the Treatment of
Pediatric Spasticity Journal of Child Neurology. ,vol. 21, pp. 189- 193 ,(2006) , 10.2310/7010.2006.00041
L. A. Koman, A. Brashear, S. Rosenfeld, H. Chambers, B. Russman, M. Rang, L. Root, E. Ferrari, J. Garcia de Yebenes Prous, B. P. Smith, C. Turkel, J. M. Walcott, P. T. Molloy, Botulinum Toxin Type A Neuromuscular Blockade in the Treatment of Equinus Foot Deformity in Cerebral Palsy: A Multicenter, Open-Label Clinical Trial Pediatrics. ,vol. 108, pp. 1062- 1071 ,(2001) , 10.1542/PEDS.108.5.1062
Gustaf Ljungman, Anders Kreuger, Svenerik Andréasson, Torsten Gordh, Stefan Sörensen, Midazolam nasal spray reduces procedural anxiety in children. Pediatrics. ,vol. 105, pp. 73- 78 ,(2000) , 10.1542/PEDS.105.1.73
Alper I. Dai, Mohammad Wasay, Safia Awan, Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity. Journal of Child Neurology. ,vol. 23, pp. 1464- 1466 ,(2008) , 10.1177/0883073808319074
Berrak Sarioglu, Gul Serdaroglu, Sarenur Tutuncuoglu, Esra A Ozer, The use of botulinum toxin type a treatment in children with spasticity Pediatric Neurology. ,vol. 29, pp. 299- 301 ,(2003) , 10.1016/S0887-8994(03)00269-8
Steffen Berweck, Florian Heinen, Use of botulinum toxin in pediatric spasticity (cerebral palsy). Movement Disorders. ,vol. 19, pp. 162- 167 ,(2004) , 10.1002/MDS.20088
Dennis MATTHEWS, Management of spasticity in children with cerebral palsy Acta Orthopaedica et Traumatologica Turcica. ,vol. 43, pp. 81- 86 ,(2009) , 10.3944/AOTT.2009.081
MCO BAX, O. FLODMARK, C. TYDEMAN, From syndrome toward disease Developmental Medicine & Child Neurology. ,vol. 49, pp. 39- 41 ,(2007) , 10.1111/J.1469-8749.2007.TB12627.X